Research Story Tip: Grants, Management Roles Keep Johns Hopkins A Leader In Hiv/Aids Clinical Trial

Date: 12/08/2020

Publication:

hopkinsmedicine.org

This World AIDS Day, HIV/AIDS researchers at Johns Hopkins Medicine learned that they now have an enhanced opportunity to help move the world toward a day when that observance is rendered obsolete. The National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID) announced Dec. 1, 2020, that Johns Hopkins Medicine will receive five of the seven-year grants awarded to 35 U.S. and international institutions to operate clinical trial units (CTUs) and coordinate HIV/AIDS clinical trials in four federally funded networks.

The three CTU grants and two leadership awards for Johns Hopkins Medicine are the most given to any one institution.

Full Article Here

Clinical Trials

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

IMPAACT 2034 - Phase I Study of the Pharmacokinetics,...

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More